# Inhibikase Therapeutics (IKT) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/IKT
## Company Profile
- Ticker: IKT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, CNS
## Stock Data
- Close: 2.41 USD
- Market cap: 224455481.2 USD
- Last updated: 2026-08-06
## Business Overview
### Pulmonary Hypertension Company
Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension.
### IKT-001
The candidate is a differentiated formulation of imatinib intended to retain pulmonary vascular activity while improving tolerability and long-term usability.
### IMPROVE-PAH
The registrational Phase 3 IMPROVE-PAH study is enrolling internationally and evaluates pulmonary vascular resistance and clinical outcomes.
## Why The Stock Is Moving

As of Aug 6, 2026, IKT closed up 0.42% at $2.41. No new same-company headline was identified in the current news window.

## Future Catalysts

- Global site activation and enrollment are advancing in the Phase 3 IMPROVE-PAH study.
- The FDA is reviewing an Orphan Drug designation application for IKT-001 in pulmonary arterial hypertension.

## Drug Assets

- IKT-001

## Recent News
- 2026-07-23 12:00 EST — [Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-fda-orphan-drug-designation-granted-to-ikt-001-b6d23765) — Source: Inhibikase Therapeutics
- 2026-07-14 12:00 EST — [Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-its-at-th-30edf4cb) — Source: Inhibikase Therapeutics
- 2026-07-02 20:01 EST — [Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-56-d71ac313) — Source: Inhibikase Therapeutics
- 2026-05-12 20:01 EST — [Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-first-quarter-2026-financial-results-and-highlights-recent-activity) — Source: Inhibikase Therapeutics
- 2026-04-07 12:00 EST — [Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial-hypertension) — Source: Inhibikase Therapeutics